Editorial: Kinase inhibitors in cancer therapy

Bibliographic Details
Main Author: Dharmendra Kumar Yadav
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-10-01
Series:Frontiers in Cell and Developmental Biology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fcell.2022.1020297/full
_version_ 1828337475766976512
author Dharmendra Kumar Yadav
author_facet Dharmendra Kumar Yadav
author_sort Dharmendra Kumar Yadav
collection DOAJ
first_indexed 2024-04-13T22:15:44Z
format Article
id doaj.art-9a906ffd4b804aa88eec71cf8f890051
institution Directory Open Access Journal
issn 2296-634X
language English
last_indexed 2024-04-13T22:15:44Z
publishDate 2022-10-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Cell and Developmental Biology
spelling doaj.art-9a906ffd4b804aa88eec71cf8f8900512022-12-22T02:27:33ZengFrontiers Media S.A.Frontiers in Cell and Developmental Biology2296-634X2022-10-011010.3389/fcell.2022.10202971020297Editorial: Kinase inhibitors in cancer therapyDharmendra Kumar Yadavhttps://www.frontiersin.org/articles/10.3389/fcell.2022.1020297/fullBax/Bcl-2kinase inhibitorsEGFR pathwayRAS-RAF-MEK-ERK pathwayRET = rearranged during transfection
spellingShingle Dharmendra Kumar Yadav
Editorial: Kinase inhibitors in cancer therapy
Frontiers in Cell and Developmental Biology
Bax/Bcl-2
kinase inhibitors
EGFR pathway
RAS-RAF-MEK-ERK pathway
RET = rearranged during transfection
title Editorial: Kinase inhibitors in cancer therapy
title_full Editorial: Kinase inhibitors in cancer therapy
title_fullStr Editorial: Kinase inhibitors in cancer therapy
title_full_unstemmed Editorial: Kinase inhibitors in cancer therapy
title_short Editorial: Kinase inhibitors in cancer therapy
title_sort editorial kinase inhibitors in cancer therapy
topic Bax/Bcl-2
kinase inhibitors
EGFR pathway
RAS-RAF-MEK-ERK pathway
RET = rearranged during transfection
url https://www.frontiersin.org/articles/10.3389/fcell.2022.1020297/full
work_keys_str_mv AT dharmendrakumaryadav editorialkinaseinhibitorsincancertherapy